Novavax Global Commercial Operations and COVID-19 Vaccine Update

Study 307 design: Lot-to-lot consistency • Subjects 18-49 years of age, N=911 • No history of COVID-19 in past 4 months AND 2 or 3 doses of COVID vaccine with last dose >6 months prior to enrollment • Priming series: 1. Moderna: 2. Pfizer: 3. Janssen/J&J: 2 doses 1 dose 4. Novavax: 2 doses 2 doses (N=125) (N=187) (N=19) (N=7) AND 3 doses (N=130) AND 3 doses (N=254) AND 2 doses (N=6) AND 3 doses (N=4) • Boost Novavax xl dose novavax Open Label ≥ 6 months NVX-COV2373 boost Lot 1 Lot 2 Immunology Prior COVID-19 vaccines +/- boost with same vaccine as primary series Lot 3 Day 0 Day 28 © 2023 NOVAVAX. All rights reserved. 445

View entire presentation